Form 4: Leap Therapeutics CEO Douglas Onsi Reports Stock Transactions
SEC Form 4 Filing
CEO Douglas Onsi reports the settlement of restricted stock units and adjustments to shareholdings following a reverse stock split.
Summary
- On March 28, 2025, Douglas E. Onsi, CEO, CFO, President, General Counsel, Treasurer, and Secretary of Leap Therapeutics, Inc., settled 32,500 restricted stock units (RSUs) previously granted on January 31, 2022.
- This settlement resulted in the issuance of 32,500 shares of Leap Therapeutics' common stock to Mr. Onsi.
- The share numbers in the report have been adjusted to reflect a 10-for-1 reverse stock split that occurred on June 20, 2023.
- Mr. Onsi also reported beneficial ownership of shares held by Nine Capital Partners, HealthCare Ventures IX, L.P. (HCV IX), and the HCV VIII Trust, but disclaims beneficial ownership except to the extent of his pecuniary interest.
- Following the reported transactions, Mr. Onsi directly owns 106,146 shares of common stock and indirectly owns 678,456 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Positives
- The settlement of RSUs indicates that Mr. Onsi has met the vesting requirements, suggesting continued service with the company.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors regarding changes in beneficial ownership.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
- Similar filings are made by executives at comparable biotech companies like Amgen, Gilead Sciences, and Biogen to report changes in their stock ownership.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the CEO's stock ownership.
- The settlement of RSUs could have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| January 31, 2022 | Date of grant for the 32,500 Restricted Stock Units (RSUs). |
| January 31, 2025 | Original vesting date of the January 2022 RSUs, settlement was deferred. |
| June 20, 2023 | Date of the 10-for-1 reverse stock split. |
| March 28, 2025 | Date of settlement for the 32,500 Restricted Stock Units (RSUs). |
| April 01, 2025 | Date of the report filing. |
Keywords
Form 4, LEAP Therapeutics, LPTX, Douglas Onsi, Restricted Stock Units, RSUs, Beneficial Ownership, Reverse Stock Split, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.